- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
The DOH Administrative Order No. 2017-0019 or the Policies and Guidelines in the Conduct of Human Immunodeficiency Virus (HIV) Testing Services (HTS) in Health Facilities defines HIV Treatment hubs as a hospital with an organized HIV and AIDS Core Team (HACT) that facilitates in-patient and out-patient prevention, treatment, care and support services to PLHIV including but not limited to antiretroviral therapy, HIV testing services, clinical management, patient monitoring, and other care and support services.
Every child should be given the best chance to start life healthy and free from preventable diseases. Mother-to-Child transmission to HIV, hepatitis B and syphilis can be effectively prevented by immunization, and screening and treatment of pregnant woman.
The Regional Framework for the Triple Elimination of Mother-to-Child Transmission of HIV, Hepatitis B and Syphilis in Asia and the Pacific 2018-2030 suggests a coordinated approach to delivering these interventions using the shared maternal, newborn and child health platform to achieve elimination.
This is the first time this regimen will be offered as an affordable, generic, fixed-dose combination, which will increase access for millions of people living with HIV in low- and middle-income countries. Below are a set of key messages and questions and answers to guide communications around the announcement and respond to media inquiries.
Keywords: HIV, ART, treatment, medicines, funding
In 2016, the Kingdom of Thailand formally decided to re-allocate responsibility for drug dependence treatment from the Ministry of Justice (MOJ) to the Ministry of Public Health (MOPH) by the end of 2018. The reforms are designed to increase voluntary access to client-centred drug dependence treatment where the MOPH will be expected to develop guidelines, operating standards and monitoring and evaluation indicators to assess performance. Although Thailand’s drug treatment system has raised significant concerns over the past 15 years, this change is intended by the Government to indicate a shift in the overall approach to drug use and dependence to one based on health and human rights.
AVAC's 2018 annual state of the field report, No Prevention, No End! looks at today's prevention crisis and offers context, analysis and strategy to turn that crisis around.
Keywords: HIV, PrEP, treatment, vaccine, prevention
This paper offers a brief analysis of these two challenges in light of current policies and practices, along with recommendati ons for overcoming them to ensure the implementati on of a drug treatment system that can result in improved health and human rights outcomes for people who use drugs and people dependant on drugs.
Antiretroviral treatment (ART) optimization is a key pillar in the AIDS Free agenda to reach the goal of ensuring 95% of all infants and children have access to lifesaving treatment.
This policy brief outlines key considerations to facilitate effective transition to more clinically appropriate regimens as optimal ARV medicines and dosage forms become available.
Keywords: HIV, ARV, paediatric, treatment, children
Every child and adolescent living with HIV should have access to antiretroviral therapy (ART). The AIDS Free component of the framework has the specific goal of ensuring 95% of all children and adolescents living with HIV have access to lifelong ART by the end of 2018. These efforts will need to be sustained until 2020, when it is estimated that treating 95% of all children and adolescents living with HIV will require providing ART to 1.4 million children (aged 0-14). and 1 million adolescents (aged 15-19).
The aim of the report is to document participation efforts and outcomes across countries, and highlight differences and constraints identified to date. In this first GLASS report data vary considerably in terms of completeness, so no attempt was made to compare AMR status at a regional or global level. However, as GLASS and country participation evolves, the data reported will help understand surveillance capacities and mechanisms of reporting across countries in all regions, and will inform further GLASS development.
This report updates the first edition, published in 2016, and reviews the progress countries have made in expanding access to life-saving DAAs. The report reviews the main challenges countries face and describes recent developments in relation to five key factors that determine access to DAA medicines: affordability, quality assurance, regulatory approval, government commitment and financing. It highlights key areas for action by ministries of health and other government decision-makers, pharmaceutical manufacturers and technical partners.